VIGONVITA-B (02630) surged more than 15% in afternoon trading, rising 14.81% to HK$88 by the time of writing, with a turnover of HK$13.33 million. The company recently announced a licensing agreement with SIMCERE PHARMA (02096) for new indications of VV116. Under the agreement, SIMCERE PHARMA will obtain exclusive licensing rights for deuterium remdesivir hydrobromide dry suspension in Greater China for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections. The collaboration leverages the strengths of both companies in R&D, production, and commercialization to accelerate the clinical development and commercialization of VV116, aiming to benefit more patients. Public data shows that VIGONVITA-B focuses on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections. As of October 21, 2025, the company has established a diversified pipeline of nine innovative drugs, with two in commercialization, four in clinical stages, and three in preclinical stages. In addition to its innovative drug pipeline, the company also has a generic drug segment, with three drugs in or nearing commercialization. Currently, VIGONVITA-B's two core products are LV232 and TPN171.